The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of concurrent pemetrexed and radiation for poor-risk stage III non-small cell lung cancer (NSCLC): Hoosier Oncology Group LUN08-129.
J. L. Feliciano
No relevant relationships to disclose
N. H. Hanna
No relevant relationships to disclose
A. Fakiris
No relevant relationships to disclose
M. Yu
No relevant relationships to disclose
W. M. Dugan
No relevant relationships to disclose
J. McClean
No relevant relationships to disclose
J. A. Bufill
No relevant relationships to disclose
S. Bhatia
No relevant relationships to disclose
J. D. Patel
Consultant or Advisory Role - Lilly (U)